Here are the 8-K filings from Freenome, Inc. (FRNM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow FRNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FRNM filings page.
Freenome, Inc. announced the launch of SimpleScreen™ Lung and an option to pair it with FDA-approved SimpleScreen™ CRC in a single blood draw, using two independently validated, indication-specific tests. SimpleScreen Lung is intended for adults ages 50 to 80 with a ≥20 pack-year smoking history who are not currently participating in guideline-recommended screening; it is a laboratory-developed test that has not been reviewed or cleared/approved by the FDA.
In an independent cohort of 172 lung cancer cases and 436 controls, SimpleScreen Lung achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value. Sensitivity was 82%, 75%, 91% and 94% for stages I through IV, respectively. SimpleScreen CRC demonstrated 81% sensitivity for colorectal cancer, 90% specificity for advanced colorectal neoplasia and a 99.9% negative predictive value in an analysis from PREEMPT CRC, which enrolled more than 48,000 participants.
Freenome, Inc. files an amendment to provide full interim financials and MD&A for Freenome Holdings, Inc. ahead of and around its July 20, 2026 business combination with Perceptive Capital Solutions Corp., which was accounted for as a reverse recapitalization.
For the six months ended June 30, 2026, Freenome generated $6.5 million in revenue, primarily from a major collaboration with Exact Sciences plus U.K. test sales, versus $1.5 million a year earlier. Net loss widened to $132.6 million, with $97.1 million of cash used in operating activities, reflecting heavy R&D and G&A spending.
At June 30, 2026 Freenome reported total assets of $398.5 million, including cash, cash equivalents and short-term marketable securities of about $102.0 million, deferred revenue of $71.1 million tied mainly to the Exact Sciences license, and significant lease and cloud-service commitments. Management states that existing liquidity plus $295.5 million in net proceeds from the SPAC/PIPE transaction is expected to fund operations for at least 12 months from issuance.